10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2010 | |||
STATEMENTS OF OPERATIONS | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 17, 2011) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
| Revenues | |||
| Sanofi-aventis collaboration revenue | $ 311,332 | 247,140 | 153,972 |
| Other collaboration revenue | 75,393 | 67,317 | 31,166 |
| Technology licensing | 40,150 | 40,013 | 40,000 |
| Net product sales | 25,254 | 18,364 | 6,249 |
| Contract research and other | 6,945 | 6,434 | 7,070 |
| Total Revenues | 459,074 | 379,268 | 238,457 |
| Expenses | |||
| Research and development | 489,252 | 398,762 | 274,903 |
| Selling, general, and administrative | 65,201 | 52,923 | 48,880 |
| Cost of goods sold | 2,093 | 1,686 | 923 |
| Total Expenses | 556,546 | 453,371 | 324,706 |
| Loss from operations | (97,472) | (74,103) | (86,249) |
| Other income (expense) | |||
| Investment income | 2,122 | 4,488 | 18,161 |
| Interest expense | (9,118) | (2,337) | (7,752) |
| Loss on early extinguishment of debt | 0 | 0 | (938) |
| Total Other Income (Expense) | (6,996) | 2,151 | 9,471 |
| Net loss before income tax expense | (104,468) | (71,952) | (76,778) |
| Income tax (benefit) expense | 0 | (4,122) | 2,351 |
| Net loss | (104,468) | (67,830) | (79,129) |
| Net loss per share, basic and diluted | (1.26) | (0.85) | (1.00) |
| Weighted average shares outstanding, basic and diluted | 82,926 | 79,782 | 78,827 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2010 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |